Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/33075| Title: | A plain language summary on the effectiveness of cladribine tablets compared with other oral treatments for multiple sclerosis: results from the MSBase registry. | Austin Authors: | Spelman, Tim;Ozakbas, Serkan;Alroughani, Raed;Terzi, Murat;Hodgkinson, Suzanne;Laureys, Guy;Kalincik, Tomas;Der Walt, Anneke Van;Yamout, Bassem;Lechner-Scott, Jeannette;Soysal, Aysun;Kuhle, Jens;Sanchez-Menoyo, Jose Luis;Morgado, Yolanda Blanco;Spitaleri, Daniele LA;Pesch, Vincent van;Horakova, Dana;Ampapa, Radek;Patti, Francesco;Macdonell, Richard A L ;Al-Asmi, Abdullah;Gerlach, Oliver;Oh, Jiwon;Altintas, Ayse;Tundia, Namita;Wong, Schiffon L;Butzkueven, Helmut | Affiliation: | MSBase Foundation, Melbourne, Australia. Dokuz Eylul University, Izmir, Turkey. Amiri Hospital, Sharq, Kuwait. Department of Neurology 19 Mayis University, Samsun, Turkey. Liverpool Hospital, Sydney, Australia. University Hospital Ghent, Ghent, Belgium. MS Centre, Department of Neurology, Royal Melbourne Hospital, Melbourne, Australia Department of Neuroscience, Central Clinical School, Monash University, Melbourne, Australia. Neurology Institute, Harley Street Medical Center, Abu Dhabi, United Arab Emirates School of Medicine & Public Health, University of Newcastle, Newcastle, Australia Bakirkoy Education & Research Hospital for Psychiatric & Neurological Diseases, Istanbul, Turkey. Multiple Sclerosis Centre, Neurology, Departments of Head, Spine & Neuromedicine, Biomedicine & Clinical Research, University Hospital Basel & University of Basel, Basel, Switzerland Department of Neurology, Galdakao-Usansolo University Hospital, Osakidetza-Basque Health Service, Biocruces-Bizkaia Health Research Institute, Galdakao, Spain. Center of Neuroimmunology, Service of Neurology, Hospital Clinic de Barcelona, Barcelona, Spain. Azienda Ospedaliera di Rilievo Nazionale San Giuseppe Moscati Avellino, Avellino, Italy. Cliniques Universitaires Saint-Luc, UCLouvain, Brussels, Belgium. Department of Neurology & Center of Clinical Neuroscience, First Faculty of Medicine, Charles University in Prague & General University Hospital, Prague, Czech Republic. Nemocnice Jihlava, Jihlava, Czech Republic. Department of Medical & Surgical Sciences & Advanced Technologies, GF Ingrassia, Catania, Italy. Neurology Neurology Unit, Department of Medicine, College of Medicine & Health Sciences & Sultan Qaboos University Hospital, SQU, Al Khodh, Oman. Academic MS Center Zuyderland, Department of Neurology, Zuyderland Medical Center, Sittard-Geleen, The Netherlands Division of Neurology, St Michael's Hospital, University of Toronto, Toronto, Canada. Koc University School of Medicine & Koc University Research Center for Translational Medicine (KUTTAM) Istanbul, Turkey. EMD Serono Research & Development Institute, Inc., Billerica, MA, USA, an affiliate of Merck KGaA. Department of Neuroscience, Central Clinical School, Monash University, Melbourne, Australia. CORe, Department of Medicine, University of Melbourne, Melbourne, Australia. American University of Beirut Medical Center, Beirut, Lebanon. Department of Neurology, John Hunter Hospital, Hunter New England Health, Newcastle, Australia. Research Center for Clinical Neuroimmunology & Neuroscience (RC2NB), University Hospital & University of Basel, Switzerland. School for Mental Health & Neuroscience, Maastricht University, Maastricht, The Netherlands. |
Issue Date: | Aug-2023 | Date: | 2023 | Publication information: | Neurodegenerative Disease Management 2023; 13(4) | Abstract: | Patient registries contain anonymous data from people who share the same medical condition. The MSBase registry contains information from over 80,000 people living with multiple sclerosis (MS) across 41 countries. Using information from the MSBase registry, the GLIMPSE (Generating Learnings In MultiPle SclErosis) study looked at real-life outcomes in 3475 people living with MS who were treated with cladribine tablets (Mavenclad®) compared with other oral treatments. Results showed that people treated with cladribine tablets stayed on treatment for longer than other treatments given by mouth. They also had fewer relapses (also called flare ups of symptoms) than people who received a different oral treatment for their MS. The results provide evidence that, compared with other oral treatments for MS, cladribine tablets are an effective medicine for people living with MS. | URI: | https://ahro.austin.org.au/austinjspui/handle/1/33075 | DOI: | 10.2217/nmt-2023-0005 | ORCID: | Journal: | Neurodegenerative Disease Management | PubMed URL: | 37287269 | ISSN: | 1758-2032 | Type: | Journal Article | Subjects: | cladribine tablets dimethyl fumarate (Tecfidera®) fingolimod (Gilenya®) lay summary multiple sclerosis relapses teriflunomide (Aubagio®) treatment options |
| Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.